ኖ Novምበር 2021 የመከላከያ ፍተሻ ነጥብ ምልክቶችን ለመዝለል ተብሎ የተነደፈው የደቡብ ኮሪያ የቤት ውስጥ ቀጣይ ትውልድ ኪምሪክ አንቲጂን ተቀባይ ቲ (CAR-T) የሴል ቴራፒ የመጀመሪያው ክሊኒካዊ ሙከራ በቅርቡ ተጀመረ።
የኮሪያ የላቀ የሳይንስ እና ቴክኖሎጂ ኢንስቲትዩት (KAIST) ረቡዕ እንዳስታወቀው የCAR-T ሕዋስ ህክምናው የደረጃ 1 ለ ክሊኒካዊ ሙከራ በአሁኑ ጊዜ በሴኡል በሚገኘው ሳምሰንግ ሜዲካል ሴንተር እየተካሄደ ነው። ሙከራው በድጋሚ ባገረሸባቸው እና ትልቅ ቢ ሴል ሊምፎማ ከተበተኑ 10 ኮሪያውያን ታካሚዎች ጋር እየተካሄደ ነው። የቧንቧ መስመር የግብይት መብቶች ከዩኒቨርሲቲው ወደ ኩሮሴል ኩባንያ ተላልፈዋል, እሱም በፕሮፌሰር ኪም ቻን-ሃይክ የተመሰረተው. ኩሮሴል የአብዮተኛውን ክሊኒካዊ ልማት ፕሮግራም ኃላፊ ነው። immunotherapy.
In addition, a Phase 2 ክሊኒካዊ ሙከራ involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for ቺምሪክ አንቲጂን ተቀባይ T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
ለማንበብ ትወድ ይሆናል የ CAR ቲ-ሴል ሕክምና በኮሪያ
የጥናቱ ግኝቶች በጥቅምት ወር ሞለኪውላር ቴራፒ ውስጥ በመስመር ላይ በታተመ ጽሑፍ ላይ ቀርበዋል.
